

Gemcitabine-based or capecitabine-based chemoradiation for resectable pancreatic cancer (SCALOP): a multicentre, randomised

Lancet Oncology, The

14, 317-326

DOI: [10.1016/s1470-2045\(13\)70021-4](https://doi.org/10.1016/s1470-2045(13)70021-4)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Risk factors for coronary calcification in older subjects The Rotterdam Coronary Calcification Study. <i>European Heart Journal</i> , 2004, 25, 48-55.	1.0	75
2	Comparison of capecitabine and 5-fluorouracil in chemoradiotherapy for locally advanced pancreatic cancer. <i>Radiation Oncology</i> , 2013, 8, 160.	1.2	11
3	Intensity modulated radiotherapy as neoadjuvant chemoradiation for the treatment of patients with locally advanced pancreatic cancer. <i>Strahlentherapie Und Onkologie</i> , 2013, 189, 738-744.	1.0	37
4	<i>ABCC11</i>/MRP8 polymorphisms affect 5-fluorouracil-induced severe toxicity and hepatic expression. <i>Pharmacogenomics</i> , 2013, 14, 1433-1448.	0.6	21
5	Chemoradiotherapy for locally advanced pancreatic cancer. <i>Lancet Oncology</i> , The, 2013, 14, 269-270.	5.1	9
7	Neoadjuvant treatment of borderline resectable and non-resectable pancreatic cancer. <i>Annals of Oncology</i> , 2013, 24, 2484-2492.	0.6	102
9	A Phase I, Dose-Finding Study of Sorafenib in Combination with Gemcitabine and Radiation Therapy in Patients with Unresectable Pancreatic Adenocarcinoma: A Grupo Espa�ol Multidisciplinario en C�ncer Digestivo (GEMCAD) Study. <i>PLoS ONE</i> , 2014, 9, e82209.	1.1	11
10	Pancreatic Cancer Treatment. <i>Journal of Drug Metabolism & Toxicology</i> , 2014, 05, .	0.1	3
11	Management of borderline and locally advanced pancreatic cancer: Where do we stand?. <i>World Journal of Gastroenterology</i> , 2014, 20, 2255.	1.4	76
13	The management of locally advanced pancreatic cancer: European Society of Digestive Oncology (ESDO) expert discussion and recommendations from the 14th ESMO/World Congress on Gastrointestinal Cancer, Barcelona. <i>Annals of Oncology</i> , 2014, 25, ii1-ii4.	0.6	3
14	Arginine deiminase augments the chemosensitivity of argininosuccinate synthetase-deficient pancreatic cancer cells to gemcitabine via inhibition of NF-�B signaling. <i>BMC Cancer</i> , 2014, 14, 686.	1.1	35
15	Phase I study of neoadjuvant accelerated short course radiation therapy with photons and capecitabine for resectable pancreatic cancer. <i>Radiotherapy and Oncology</i> , 2014, 110, 160-164.	0.3	25
16	Phase II Trial of Cetuximab and Conformal Radiotherapy Only in Locally Advanced Pancreatic Cancer with Concurrent Tissue Sampling Feasibility Study. <i>Translational Oncology</i> , 2014, 7, 55-64.	1.7	16
18	Phase I/II study of verteporfin photodynamic therapy in locally advanced pancreatic cancer. <i>British Journal of Cancer</i> , 2014, 110, 1698-1704.	2.9	316
19	Resectable, Borderline Resectable, and Locally Advanced Pancreatic Cancer: What Does It Matter?. <i>Current Oncology Reports</i> , 2014, 16, 366.	1.8	26
20	Locally Advanced Pancreatic Cancer: The Role of Definitive Chemoradiotherapy. <i>Clinical Oncology</i> , 2014, 26, 560-568.	0.6	42
21	A phase I and pharmacokinetic study of capecitabine in combination with radiotherapy in patients with localised inoperable pancreatic cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 74, 131-139.	1.1	0
22	Management of Borderline Resectable Pancreatic Cancer. <i>Seminars in Radiation Oncology</i> , 2014, 24, 105-112.	1.0	59

#	ARTICLE	IF	CITATIONS
23	Enhanced Tumor Delivery of Gemcitabine via PEG-DSPE/TPGS Mixed Micelles. <i>Molecular Pharmaceutics</i> , 2014, 11, 1140-1150.	2.3	53
24	Management Options in Locally Advanced Pancreatic Cancer. <i>Current Oncology Reports</i> , 2014, 16, 388.	1.8	29
25	Selective inhibition of unfolded protein response induces apoptosis in pancreatic cancer cells. <i>Oncotarget</i> , 2014, 5, 4881-4894.	0.8	77
26	Selection criteria in resectable pancreatic cancer: A biological and morphological approach. <i>World Journal of Gastroenterology</i> , 2014, 20, 11210.	1.4	31
27	Evolving Treatment Options for Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 167-172.	2.3	4
28	Salvage Pancreaticoduodenectomy After Complete Response to Chemoradiotherapy for a Previously Unresectable Pancreatic Adenosquamous Carcinoma. <i>Medicine (United States)</i> , 2015, 94, e499.	0.4	4
29	Pancreatic Cancer: Progress in Systemic Therapy. <i>Gastrointestinal Tumors</i> , 2014, 1, 167-179.	0.3	11
32	Prospective study of cetuximab and gemcitabine in combination with radiation therapy: feasibility and efficacy in locally advanced pancreatic head cancer. <i>Radiation Oncology</i> , 2015, 10, 255.	1.2	10
33	Neoadjuvant modified FOLFIRINOX and chemoradiation therapy for locally advanced pancreatic cancer improves resectability. <i>Journal of Surgical Oncology</i> , 2015, 111, 1028-1034.	0.8	65
34	Management of cancer of the exocrine pancreas. , 0, , 212-223.		0
35	Concurrent radiotherapy with oral fluoropyrimidine versus gemcitabine in locally advanced pancreatic cancer: a systematic review and meta-analysis. <i>OncoTargets and Therapy</i> , 2015, 8, 3315.	1.0	6
36	Modeling Combined Chemotherapy and Particle Therapy for Locally Advanced Pancreatic Cancer. <i>Frontiers in Oncology</i> , 2015, 5, 145.	1.3	23
37	The Emerging Genetic Basis and Its Clinical Implication in Pancreatic Cancer. <i>Gastrointestinal Tumors</i> , 2015, 2, 131-143.	0.3	0
38	Stereotactic body radiotherapy using CyberKnife for locally advanced unresectable and metastatic pancreatic cancer. <i>World Journal of Gastroenterology</i> , 2015, 21, 8156.	1.4	36
39	Improving Adherence to Cancer Treatment by Addressing Quality of Life in Patients With Advanced Gastrointestinal Cancers. <i>Journal of Pain and Symptom Management</i> , 2015, 50, 321-327.	0.6	34
41	Comparison of investigator-delineated gross tumor volumes and quality assurance in pancreatic cancer: Analysis of the pretrial benchmark case for the SCALOP trial. <i>Radiotherapy and Oncology</i> , 2015, 117, 432-437.	0.3	22
42	SBRT in pancreatic cancer: What is the therapeutic window?. <i>Radiotherapy and Oncology</i> , 2015, 114, 109-116.	0.3	85
43	Advances in Chemotherapy for Pancreatic Cancer. <i>Indian Journal of Surgical Oncology</i> , 2015, 6, 47-56.	0.3	5

#	ARTICLE	IF	CITATIONS
44	Pancreatic cancer: current management and treatment strategies. <i>Postgraduate Medical Journal</i> , 2015, 91, 601-607.	0.9	22
45	Treatment Approaches to Locally Advanced Pancreatic Adenocarcinoma. <i>Hematology/Oncology Clinics of North America</i> , 2015, 29, 741-759.	0.9	9
47	Approach to Patients With Pancreatic Cancer Without Detectable Metastases. <i>Journal of Clinical Oncology</i> , 2015, 33, 1770-1778.	0.8	117
48	Stage III pancreatic cancer and the role of irreversible electroporation. <i>BMJ, The</i> , 2015, 350, h521-h521.	3.0	38
49	Intensity-Modulated Radiation Therapy. , 2015, , .		7
50	Pancreatic cancer: from state-of-the-art treatments to promising novel therapies. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 319-334.	12.5	489
51	Health-Related Quality of Life in SCALOP, a Randomized Phase 2 Trial Comparing Chemoradiation Therapy Regimens in Locally Advanced Pancreatic Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 810-818.	0.4	32
52	Safety and Feasibility of Irreversible Electroporation (IRE) in Patients with Locally Advanced Pancreatic Cancer: Results of a Prospective Study. <i>Digestive Surgery</i> , 2015, 32, 90-97.	0.6	114
53	Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2015, 26, v56-v68.	0.6	1,015
54	State of the art and future directions of pancreatic ductal adenocarcinoma therapy. , 2015, 155, 80-104.		82
55	Activation of protein phosphatase 2A tumor suppressor as potential treatment of pancreatic cancer. <i>Molecular Oncology</i> , 2015, 9, 889-905.	2.1	51
56	Novel directions in neoadjuvant therapy for pancreas adenocarcinoma. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015, 9, 585-601.	1.4	3
57	The Role of Radiation Therapy in Pancreatic Ductal Adenocarcinoma in the Neoadjuvant and Adjuvant Settings. <i>Seminars in Oncology</i> , 2015, 42, 144-162.	0.8	21
58	Pancreatic ductal adenocarcinoma: From genetics to biology to radiobiology to oncoimmunology and all the way back to the clinic. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2015, 1855, 61-82.	3.3	46
59	Multimodality Therapy in Patients With Borderline Resectable or Locally Advanced Pancreatic Cancer: Importance of Locoregional Therapies for a Systemic Disease. <i>Journal of Oncology Practice</i> , 2016, 12, 915-923.	2.5	19
60	Localized Pancreatic Cancer: Multidisciplinary Management. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 35, e217-e226.	1.8	23
61	Systematic review of outcomes after distal pancreatectomy with coeliac axis resection for locally advanced pancreatic cancer. <i>British Journal of Surgery</i> , 2016, 103, 941-949.	0.1	67
62	SEOM Clinical Guideline for the treatment of pancreatic cancer (2016). <i>Clinical and Translational Oncology</i> , 2016, 18, 1172-1178.	1.2	27

#	ARTICLE	IF	CITATIONS
63	Role of Radiotherapy in Locally Advanced Pancreatic Cancer. , 2016, , 1-26.		0
64	ARCI: A phase II trial of the HIV protease inhibitor Nelfinavir in combination with chemoradiation for locally advanced inoperable pancreatic cancer. Radiotherapy and Oncology, 2016, 119, 306-311.	0.3	43
65	Hypofractionated Conformal Radiotherapy with Concurrent Full-Dose Gemcitabine Versus Standard Fractionation Radiotherapy with Concurrent Fluorouracil for Unresectable Pancreatic Cancer: a Multi-Institution Experience. Journal of Gastrointestinal Cancer, 2016, 47, 196-201.	0.6	5
66	Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib. JAMA - Journal of the American Medical Association, 2016, 315, 1844.	3.8	801
67	Neoadjuvant therapy for pancreatic cancer: an ongoing debate. Therapeutic Advances in Gastroenterology, 2016, 9, 429-436.	1.4	10
68	Prognostic relevance of molecular subtypes and master regulators in pancreatic ductal adenocarcinoma. BMC Cancer, 2016, 16, 632.	1.1	130
69	Comparison of investigator-delineated gross tumour volumes and quality assurance in pancreatic cancer: Analysis of the on-trial cases for the SCALOP trial. Radiotherapy and Oncology, 2016, 120, 212-216.	0.3	23
70	The rationale of combined radiotherapy and chemotherapy “ Joint action of Castor and Pollux. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2016, 30, 515-528.	1.0	19
71	Management of radiation and chemotherapy related acute toxicity in gastrointestinal cancer. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2016, 30, 655-664.	1.0	36
72	Chemotherapeutic agents for GI tumor chemoradiotherapy overview of chemotherapeutic agents to be combined with radiotherapy in the GI tract and their potential as radiosensitizers. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2016, 30, 529-535.	1.0	3
73	Recent Advances and Prospects for Multimodality Therapy in Pancreatic Cancer. Seminars in Radiation Oncology, 2016, 26, 320-337.	1.0	21
74	Progression-free survival as a surrogate for overall survival in first-line chemotherapy for advanced pancreatic cancer. European Journal of Cancer, 2016, 65, 11-20.	1.3	19
76	Pancreatic cancer chemoradiotherapy. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2016, 30, 617-628.	1.0	11
77	Phase 1B trial of Nab-paclitaxel plus gemcitabine, capecitabine, and cisplatin (PAXG regimen) in patients with unresectable or borderline resectable pancreatic adenocarcinoma. British Journal of Cancer, 2016, 115, 290-296.	2.9	29
78	Ablation Strategies for Locally Advanced Pancreatic Cancer. Digestive Surgery, 2016, 33, 351-359.	0.6	36
79	Systemic Therapy in Pancreatic Cancer. , 2016, , 247-273.		1
80	Locally Advanced, Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology, 2016, 34, 2654-2668.	0.8	292
81	Induction Chemotherapy Followed by Concurrent Full-dose Gemcitabine and Intensity-modulated Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2016, 39, 1-7.	0.6	24

#	ARTICLE	IF	CITATIONS
82	Intensity modulated radiation therapy reduces gastrointestinal toxicity in locally advanced pancreas cancer. <i>Practical Radiation Oncology</i> , 2016, 6, 78-85.	1.1	30
83	The role of neoadjuvant therapy in pancreatic cancer: a review. <i>Future Oncology</i> , 2016, 12, 669-685.	1.1	32
84	Neoadjuvant multimodal treatment of pancreatic ductal adenocarcinoma. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 98, 309-324.	2.0	35
85	Current standards and new innovative approaches for treatment of pancreatic cancer. <i>European Journal of Cancer</i> , 2016, 57, 10-22.	1.3	138
86	Focal Radiation Therapy Dose Escalation Improves Overall Survival in Locally Advanced Pancreatic Cancer Patients Receiving Induction Chemotherapy and Consolidative Chemoradiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 94, 755-765.	0.4	285
87	Palliative Management of Unresectable Pancreas Cancer. <i>Surgical Oncology Clinics of North America</i> , 2016, 25, 327-337.	0.6	12
88	Contemporary Management of Borderline Resectable and Locally Advanced Unresectable Pancreatic Cancer. <i>Oncologist</i> , 2016, 21, 178-187.	1.9	47
89	Role of Radiation Therapy. , 2016, , 107-124.		0
90	Dual inhibition of nuclear factor kappa-B and Mdm2 enhance the antitumor effect of radiation therapy for pancreatic cancer. <i>Cancer Letters</i> , 2016, 370, 177-184.	3.2	20
91	International Association of Pancreatology (IAP)/European Pancreatic Club (EPC) consensus review of guidelines for the treatment of pancreatic cancer. <i>Pancreatology</i> , 2016, 16, 14-27.	0.5	81
93	Can Stereotactic Body Radiation Therapy Be a Viable and Efficient Therapeutic Option for Unresectable Locally Advanced Pancreatic Adenocarcinoma? Results of a Phase 2 Study. <i>Technology in Cancer Research and Treatment</i> , 2017, 16, 295-301.	0.8	80
94	Dose escalation in locally advanced pancreatic cancer patients receiving chemoradiotherapy. <i>Radiotherapy and Oncology</i> , 2017, 123, 438-445.	0.3	48
95	What treatment in 2017 for inoperable pancreatic cancers?. <i>Annals of Oncology</i> , 2017, 28, 1473-1483.	0.6	30
97	Analysis of Predictors of Resection and Survival in Locally Advanced Stage III Pancreatic Cancer: Does the Nature of Chemotherapy Regimen Influence Outcomes?. <i>Annals of Surgical Oncology</i> , 2017, 24, 1406-1413.	0.7	45
98	Modelling duodenum radiotherapy toxicity using cohort dose-volume-histogram data. <i>Radiotherapy and Oncology</i> , 2017, 123, 431-437.	0.3	17
99	Clinical effects of chemoradiotherapy in pursuit of optimal treatment of locally advanced unresectable pancreatic cancer. <i>British Journal of Radiology</i> , 2017, 90, 20170165.	1.0	12
100	Correlation of 18F-Fluorodeoxyglucose Positron Emission Tomography Parameters with Patterns of Disease Progression in Locally Advanced Pancreatic Cancer after Definitive Chemoradiotherapy. <i>Clinical Oncology</i> , 2017, 29, 370-377.	0.6	25
101	Long-term results and recurrence patterns from SCALOP: a phase II randomised trial of gemcitabine- or capecitabine-based chemoradiation for locally advanced pancreatic cancer. <i>British Journal of Cancer</i> , 2017, 116, 1264-1270.	2.9	50

#	ARTICLE	IF	CITATIONS
102	Selecting patients for resection after primary chemotherapy for non-metastatic pancreatic adenocarcinoma. <i>Annals of Oncology</i> , 2017, 28, 2786-2792.	0.6	87
103	Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 1028-1061.	2.3	762
104	Surgical Indications of Distal Pancreatectomy with Celiac Axis Resection for Pancreatic Body/Tail Cancer. <i>World Journal of Surgery</i> , 2017, 41, 258-266.	0.8	28
105	Chemotherapy and radiotherapy for pancreatic cancer. , 2017, , 1032-1041.e3.		0
106	Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1338.	1.8	431
107	Locally Advanced Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline Summary. <i>Journal of Oncology Practice</i> , 2017, 13, 265-269.	2.5	56
108	The role of induction chemotherapy + chemoradiotherapy in localised pancreatic cancer: initial experience in Scotland. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 683-695.	0.6	12
109	Nonmetastatic pancreatic cancer. <i>Strahlentherapie Und Onkologie</i> , 2018, 194, 627-637.	1.0	4
110	Adjuvant chemoradiation for gastric carcinoma: State of the art and perspectives. <i>Clinical and Translational Radiation Oncology</i> , 2018, 10, 13-22.	0.9	18
113	Cure of unresectable, locally advanced pancreatic cancer after multidisciplinary therapy. <i>Journal of Cancer Research and Practice</i> , 2018, 5, 27-31.	0.2	3
114	Locally advanced pancreas cancer: Staging and goals of therapy. <i>Surgery</i> , 2018, 163, 1053-1062.	1.0	53
115	Resectable and Borderline Resectable Pancreatic Cancer. <i>Practical Guides in Radiation Oncology</i> , 2018, , 199-229.	0.0	0
116	Chemotherapy and radiotherapy for advanced pancreatic cancer. <i>The Cochrane Library</i> , 2018, 2018, CD011044.	1.5	80
117	Role of Radiotherapy in Locally Advanced Pancreatic Cancer. , 2018, , 1435-1460.		0
118	Stomach Doseâ€Volume Predicts Acute Gastrointestinal Toxicity in Chemoradiotherapy for Locally Advanced Pancreatic Cancer. <i>Clinical Oncology</i> , 2018, 30, 418-426.	0.6	8
119	Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 310-320.	2.3	476
120	Management of unresectable, locally advanced pancreatic adenocarcinoma. <i>Clinical and Translational Oncology</i> , 2018, 20, 113-118.	1.2	3
121	Essential role of radiation therapy for the treatment of pancreatic cancer. <i>Strahlentherapie Und Onkologie</i> , 2018, 194, 185-195.	1.0	21

#	ARTICLE	IF	CITATIONS
122	Results of a prospective phase 2 clinical trial of induction gemcitabine/capecitabine followed by stereotactic ablative radiation therapy in borderline resectable or locally advanced pancreatic adenocarcinoma. <i>Practical Radiation Oncology</i> , 2018, 8, 95-106.	1.1	34
123	The Evolving Role of Radiation in Pancreatic Cancer. <i>Surgical Clinics of North America</i> , 2018, 98, 113-125.	0.5	21
124	Locally advanced pancreatic cancer: An emerging entity. <i>Current Problems in Cancer</i> , 2018, 42, 12-25.	1.0	13
125	Technical aspects of modern radiation therapy for pancreatic adenocarcinoma: field design, motion management, dosing, and concurrent therapy. <i>Annals of Pancreatic Cancer</i> , 2018, 1, 21-21.	1.2	2
126	Clinical results of dynamic tumor tracking intensity-modulated radiotherapy with real-time monitoring for pancreatic cancers using a gimbal mounted linac. <i>Oncotarget</i> , 2018, 9, 23628-23635.	0.8	12
127	Review and current state of radiation therapy for locally advanced pancreatic adenocarcinoma. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 1027-1036.	0.6	8
128	Percutaneous irreversible electroporation with systemic treatment for locally advanced pancreatic adenocarcinoma. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 275-281.	0.6	47
129	Evaluating Progression-Free Survival as a Surrogate Outcome for Health-Related Quality of Life in Oncology. <i>JAMA Internal Medicine</i> , 2018, 178, 1586.	2.6	92
130	Improving prediction of surgical resectability over current staging guidelines in patients with pancreatic cancer who receive stereotactic body radiation therapy. <i>Advances in Radiation Oncology</i> , 2018, 3, 601-610.	0.6	5
131	Incidence and risk factors for abdominal occult metastatic disease in patients with pancreatic adenocarcinoma. <i>Journal of Surgical Oncology</i> , 2018, 118, 1277-1284.	0.8	30
132	Effects of chemoradiotherapy and chemotherapy on survival of patients with locally advanced pancreatic cancer. <i>Medicine (United States)</i> , 2018, 97, e12260.	0.4	6
133	Pancreatic cancer: French clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE). <i>TJ ETQq1 1 0.784314 rgBT/Ove</i>	0.4	104
134	The Role of Consolidation Chemoradiotherapy in Locally Advanced Pancreatic Cancer Receiving Chemotherapy: An Updated Systematic Review and Meta-Analysis. <i>Cancer Research and Treatment</i> , 2018, 50, 562-574.	1.3	16
135	The Art of War and oncology: applying the principles of strategy and tactics to greater effect in the era of targeted therapy. <i>Annals of Translational Medicine</i> , 2018, 6, 168-168.	0.7	1
137	Initial experience with intensity modulated proton therapy for intact, clinically localized pancreas cancer: Clinical implementation, dosimetric analysis, acute treatment-related adverse events, and patient-reported outcomes. <i>Advances in Radiation Oncology</i> , 2018, 3, 314-321.	0.6	20
138	Effectiveness and Safety of Simultaneous Integrated Boost-Proton Beam Therapy for Localized Pancreatic Cancer. <i>Technology in Cancer Research and Treatment</i> , 2018, 17, 153303381878387.	0.8	15
139	Intensity-modulated radiotherapy with systemic chemotherapy improves survival in patients with nonmetastatic unresectable pancreatic adenocarcinoma: A propensity score-matched, nationwide, population-based cohort study. <i>Radiotherapy and Oncology</i> , 2018, 129, 326-332.	0.3	19
140	MRI guided stereotactic radiotherapy for locally advanced pancreatic cancer. <i>British Journal of Radiology</i> , 2018, 91, 20170563.	1.0	33

#	ARTICLE	IF	CITATIONS
141	Inhibition of endoplasmic-reticulum-stress-mediated autophagy enhances the effectiveness of chemotherapeutics on pancreatic cancer. <i>Journal of Translational Medicine</i> , 2018, 16, 190.	1.8	47
143	Simulation study of dosimetric effect in proton beam therapy using concomitant boost technique for unresectable pancreatic cancers. <i>Japanese Journal of Radiology</i> , 2018, 36, 456-461.	1.0	5
144	New Hope for Pancreatic Ductal Adenocarcinoma Treatment Targeting Endoplasmic Reticulum Stress Response: A Systematic Review. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2468.	1.8	27
145	Borderline resectable pancreatic cancer. Challenges and controversies. <i>Cancer Treatment Reviews</i> , 2018, 68, 124-135.	3.4	27
147	Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches. <i>Radiation Oncology</i> , 2019, 14, 141.	1.2	285
149	An update on treatment options for pancreatic adenocarcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591987556.	1.4	144
150	Conversion Surgery for Advanced Pancreatic Cancer. <i>Journal of Clinical Medicine</i> , 2019, 8, 1945.	1.0	20
151	The Prognosis Value of PIWIL1 and PIWIL2 Expression in Pancreatic Cancer. <i>Journal of Clinical Medicine</i> , 2019, 8, 1275.	1.0	15
152	Environmental Risk Factors of Pancreatic Cancer. <i>Journal of Clinical Medicine</i> , 2019, 8, 1427.	1.0	35
153	Intrasplenic Pancreatic Pseudocyst after Chemoradiation of a Pancreatic Adenocarcinoma Mimicking Progressive Disease: A Case Report and Review of the Literature. <i>Case Reports in Oncological Medicine</i> , 2019, 2019, 1-4.	0.2	1
154	Current Clinical Strategies of Pancreatic Cancer Treatment and Open Molecular Questions. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4543.	1.8	68
155	A PARP inhibitor in pancreatic cancer: Enhancement anti-tumour activity of chemoradiation therapy against pancreatic cancer?. <i>EBioMedicine</i> , 2019, 40, 9-10.	2.7	2
156	Optimizing the management of locally advanced pancreatic cancer with a focus on induction chemotherapy: Expert opinion based on a review of current evidence. <i>Cancer Treatment Reviews</i> , 2019, 77, 1-10.	3.4	48
157	Dose escalated concurrent chemo-radiation in borderline resectable and locally advanced pancreatic cancers with tomotherapy based intensity modulated radiotherapy: a phase II study. <i>Journal of Gastrointestinal Oncology</i> , 2019, 10, 474-482.	0.6	5
158	Concurrent chemoradiotherapy using proton beams for unresectable locally advanced pancreatic cancer. <i>Radiotherapy and Oncology</i> , 2019, 136, 37-43.	0.3	34
159	Comparison of the dose escalation potential for two hypofractionated radiotherapy regimens for locally advanced pancreatic cancer. <i>Clinical and Translational Radiation Oncology</i> , 2019, 16, 21-27.	0.9	4
160	Sustained co-delivery of gemcitabine and cis-platinum via biodegradable thermo-sensitive hydrogel for synergistic combination therapy of pancreatic cancer. <i>Nano Research</i> , 2019, 12, 1389-1399.	5.8	69
162	Study protocol: a multi-centre randomised study of induction chemotherapy followed by capecitabine ± nelfinavir with high- or standard-dose radiotherapy for locally advanced pancreatic cancer (SCALOP-2). <i>BMC Cancer</i> , 2019, 19, 121.	1.1	11

#	ARTICLE	IF	CITATIONS
163	Changing paradigm of radiation therapy for the treatment of pancreatic cancer. <i>Precision Radiation Oncology</i> , 2019, 3, 149-162.	0.4	0
164	Intraoperative Irreversible Electroporation in Locally Advanced Pancreatic Cancer: A Guide for the Interventional Radiologist. <i>Seminars in Interventional Radiology</i> , 2019, 36, 386-391.	0.3	6
165	A Preoperative Prognostic Scoring System to Predict Prognosis for Resectable Pancreatic Cancer: Who Will Benefit from Upfront Surgery?. <i>Journal of Gastrointestinal Surgery</i> , 2019, 23, 990-996.	0.9	21
166	Phase 2 Trial of Neoadjuvant FOLFIRINOX and Intensity Modulated Radiation Therapy Concurrent With Fixed-Dose Rate-Gemcitabine in Patients With Borderline Resectable Pancreatic Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 106, 124-133.	0.4	28
167	The impact of immunotherapy on the survival of pancreatic adenocarcinoma patients who do not receive definitive surgery of the tumor. <i>Clinical and Translational Radiation Oncology</i> , 2020, 24, 34-40.	0.9	11
168	Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma. <i>Ca-A Cancer Journal for Clinicians</i> , 2020, 70, 375-403.	157.7	237
169	Hypofractionated intensity-modulated radiotherapy with concurrent chemotherapy for elderly patients with locally advanced pancreatic carcinoma. <i>Radiation Oncology</i> , 2020, 15, 264.	1.2	7
170	Emerging insights on drug delivery by fatty acid mediated synthesis of lipophilic prodrugs as novel nanomedicines. <i>Journal of Controlled Release</i> , 2020, 326, 556-598.	4.8	49
171	The Association of the Sequence of Immunotherapy With the Survival of Unresectable Pancreatic Adenocarcinoma Patients: A Retrospective Analysis of the National Cancer Database. <i>Frontiers in Oncology</i> , 2020, 10, 1518.	1.3	2
172	Low Systemic Inflammation Response Index Predicts Good Prognosis in Locally Advanced Pancreatic Carcinoma Patients Treated with Concurrent Chemoradiotherapy. <i>Gastroenterology Research and Practice</i> , 2020, 2020, 1-8.	0.7	14
173	Stereotactic body radiotherapy vs conventionally fractionated chemoradiation in locally advanced pancreatic cancer: A multicenter caseâ€control study (PAULAâ€1). <i>Cancer Medicine</i> , 2020, 9, 7879-7887.	1.3	16
174	Efficacy and feasibility of proton beam radiotherapy using the simultaneous integrated boost technique for locally advanced pancreatic cancer. <i>Scientific Reports</i> , 2020, 10, 21712.	1.6	12
175	The Emerging Role of miRNAs for the Radiation Treatment of Pancreatic Cancer. <i>Cancers</i> , 2020, 12, 3703.	1.7	13
176	Evaluating dosimetric constraints for carbon ion radiotherapy in the treatment of locally advanced pancreatic cancer. <i>Radiation Oncology</i> , 2020, 15, 101.	1.2	3
177	Benefits of Conversion Surgery after Multimodal Treatment for Unresectable Pancreatic Ductal Adenocarcinoma. <i>Cancers</i> , 2020, 12, 1428.	1.7	10
178	(3E,5E)-3,5-Bis(pyridin-3-methylene)-tetrahydrothiopyran-4-one enhances the inhibitory effect of gemcitabine on pancreatic cancer cells. <i>Bioorganic Chemistry</i> , 2020, 101, 104022.	2.0	2
179	Basics and Frontiers on Pancreatic Cancer for Radiation Oncology: Target Delineation, SBRT, SIB Technique, MRgRT, Particle Therapy, Immunotherapy and Clinical Guidelines. <i>Cancers</i> , 2020, 12, 1729.	1.7	26
181	Conventionally fractionated radiation therapy versus stereotactic body radiation therapy for locally advanced pancreatic cancer (CRISP): An international systematic review and metaâ€analysis. <i>Cancer</i> , 2020, 126, 2120-2131.	2.0	72

#	ARTICLE	IF	CITATIONS
182	Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 285-294.	3.7	152
183	Higher Biologically Effective Dose Predicts Survival in SBRT of Pancreatic Cancer: A Multicentric Analysis (PAULA-1). <i>Anticancer Research</i> , 2020, 40, 465-472.	0.5	35
185	Circulating biomarkers and outcomes from a randomised phase 2 trial of gemcitabine versus capecitabine-based chemoradiotherapy for pancreatic cancer. <i>British Journal of Cancer</i> , 2021, 124, 581-586.	2.9	9
186	The Match between Molecular Subtypes, Histology and Microenvironment of Pancreatic Cancer and Its Relevance for Chemoresistance. <i>Cancers</i> , 2021, 13, 322.	1.7	19
187	Extended pancreatectomy in patients with pancreatic cancer. <i>Suizo</i> , 2021, 36, 82-88.	0.1	0
188	Irreversible electroporation of locally advanced pancreatic cancer. <i>Seminars in Oncology</i> , 2021, 48, 84-94.	0.8	10
189	Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 128-138.	3.7	89
190	SEOM clinical guidelines for pancreatic and biliary tract cancer (2020). <i>Clinical and Translational Oncology</i> , 2021, 23, 988-1000.	1.2	23
191	Controversies in radiotherapy for pancreas cancer. <i>Journal of Surgical Oncology</i> , 2021, 123, 1460-1466.	0.8	7
192	Conversion surgery in patients with pancreatic cancer and peritoneal metastasis. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, S110-S117.	0.6	14
193	EUSâ€­guided hydrogel microparticle injection in a cadaveric model. <i>Journal of Applied Clinical Medical Physics</i> , 2021, 22, 83-91.	0.8	10
194	Thumbprinting Locally Advanced Pancreatic Cancer: Have We Developed the Optimal Staging System?. <i>Annals of Surgical Oncology</i> , 2021, 28, 5808-5810.	0.7	1
195	Conversion surgery for initially unresectable pancreatic ductal adenocarcinoma following induction therapy: a systematic review of the published literature. <i>Updates in Surgery</i> , 2022, 74, 43-53.	0.9	11
196	Pentraxin 3 is a stromally-derived biomarker for detection of pancreatic ductal adenocarcinoma. <i>Npj Precision Oncology</i> , 2021, 5, 61.	2.3	16
197	Local Control and Survival After Induction Chemotherapy and Ablative Radiation Versus Resection for Pancreatic Ductal Adenocarcinoma With Vascular Involvement. <i>Annals of Surgery</i> , 2021, 274, 894-901.	2.1	15
198	Adjuvant Treatment in Pancreatic Cancer: Shaping the Future of the Curative Setting. <i>Frontiers in Oncology</i> , 2021, 11, 695627.	1.3	10
199	Conversion therapy, palliative chemotherapy and surgery, which of these is the best treatment for locally advanced and advanced pancreatic cancer?. <i>Anti-Cancer Drugs</i> , 2021, Publish Ahead of Print, .	0.7	1
201	Pancreatic Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 851.	3.8	658

#	ARTICLE	IF	CITATIONS
203	Căncer de pâncreas. <i>Medicine</i> , 2021, 13, 1345-1352.	0.0	0
204	The impact of early tumor shrinkage on conversion surgery and the survival in patients with unresectable locally advanced pancreatic cancer. <i>Surgery Today</i> , 2021, 51, 1099-1107.	0.7	5
205	Nonsurgical therapies for resected and unresected pancreatic cancer in Europe and USA in 2003–2014: a large international population-based study. <i>International Journal of Cancer</i> , 2018, 143, 3227-3239.	2.3	25
206	Improved Survival in Patients with Resected Pancreatic Carcinoma Using Postoperative Intensity-Modulated Radiotherapy and Regional Intra-Arterial Infusion Chemotherapy. <i>Medical Science Monitor</i> , 2017, 23, 2315-2323.	0.5	5
207	The Evolving Field of Stereotactic Body Radiation Therapy in Pancreatic Cancer. <i>Pancreas (Fairfax, Va)</i> , 2019, 3, 9-14.	1.4	18
208	Possibilities of palliative chemotherapy in patients with locally advanced and metastatic pancreatic cancer. <i>Issledovaniĭ I Praktika V Medicine</i> , 2020, 7, 118-134.	0.1	3
209	Superior efficacy of the antifungal agent ciclopirox olamine over gemcitabine in pancreatic cancer models. <i>Oncotarget</i> , 2018, 9, 10360-10374.	0.8	28
210	Neoadjuvant strategies for pancreatic cancer. <i>World Journal of Gastroenterology</i> , 2014, 20, 9374-83.	1.4	17
211	S-1 in the treatment of pancreatic cancer. <i>World Journal of Gastroenterology</i> , 2014, 20, 15110.	1.4	41
212	Concurrent Chemoradiotherapy Versus Chemotherapy Alone for Unresectable Locally Advanced Pancreatic Cancer: A Retrospective Cohort Study. <i>Cancer Research and Treatment</i> , 2016, 48, 1045-1055.	1.3	10
213	Induction Chemotherapy with Gemcitabine and Cisplatin Followed by Simultaneous Integrated Boost–Intensity Modulated Radiotherapy with Concurrent Gemcitabine for Locally Advanced Unresectable Pancreatic Cancer: Results from a Feasibility Study. <i>Cancer Research and Treatment</i> , 2017, 49, 1022-1032.	1.3	9
214	Neoadjuvant radiotherapeutic strategies in pancreatic cancer. <i>World Journal of Gastrointestinal Oncology</i> , 2016, 8, 186.	0.8	13
215	Current and emerging therapeutic strategies in pancreatic cancer: Challenges and opportunities. <i>World Journal of Gastroenterology</i> , 2021, 27, 6572-6589.	1.4	14
216	Updates and new directions in the use of radiation therapy for the treatment of pancreatic adenocarcinoma: dose, sensitization, and novel technology. <i>Cancer and Metastasis Reviews</i> , 2021, 40, 879-889.	2.7	2
219	Pancreatic CancerPancreatic Cancer. , 2015, , 315-336.		0
220	Long-Term Progression-Free Survival in a Patient with Locally Advanced, Unresectable Pancreatic Adenocarcinoma. <i>Cureus</i> , 2015, 7, e406.	0.2	1
221	Outcome Analysis of Chemoradiation in Unresectable Pancreatic Cancer Focusing on Treatment Sequencing Strategy. <i>Anticancer Research</i> , 2016, 36, 5455-5462.	0.5	0
222	Pancreatic Cancer: Background and Clinical Evidence. , 2017, , 73-90.		0

#	ARTICLE	IF	CITATIONS
223	Chemotherapy in the Management of Pancreatic Cancer. , 2017, , 387-419.		0
224	Which patients with locally advanced pancreatic cancer treated with induction chemotherapy are most likely to benefit from post-induction chemoradiotherapy?. International Journal of Hepatobiliary and Pancreatic Diseases, 2018, 8, 1.	0.2	0
225	Treatment Sequencing for Locally Advanced Pancreatic Cancer. , 2019, , 105-112.		0
226	Role of Radiation for Locally Advanced Pancreatic Cancer. , 2019, , 113-132.		0
227	Toxicity Management for Upper Abdomen Tumors in Radiation Oncology. , 2020, , 171-229.		1
228	Nonsurgical Management of Pancreatic Adenocarcinoma. , 2021, , 1-22.		0
229	Pancreatic cancer treatment. Suizo, 2020, 35, 193-200.	0.1	0
230	A study of biomacromolecular changes in dandelion root extract induced PANC-1 cells apoptosis using FTIR microspectroscopy. Infrared Physics and Technology, 2022, 120, 103995.	1.3	2
231	Elective Target Coverage for Pancreatic Cancer: When Less Does Not Clearly Achieve More. International Journal of Radiation Oncology Biology Physics, 2022, 112, 143-145.	0.4	7
232	Could Total Neoadjuvant Therapy Followed by Surgical Resection Be the New Standard of Care in Pancreatic Cancer? A Systematic Review and Meta-Analysis. Journal of Clinical Medicine, 2022, 11, 812.	1.0	6
233	Radiation therapy of pancreatic cancers. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2022, 26, 259-265.	0.6	1
234	Association of facility type with overall survival in patients with nonsurgically managed pancreatic cancer. Future Oncology, 2022, 18, 1273-1284.	1.1	2
235	Factors associated with long-term survival in gemcitabine-concurrent proton radiotherapy for non-metastatic locally advanced pancreatic cancer: a single-center retrospective study. Radiation Oncology, 2022, 17, 32.	1.2	5
236	Clinical challenges associated with utility of neoadjuvant treatment in patients with pancreatic ductal adenocarcinoma. European Journal of Surgical Oncology, 2022, 48, 1198-1208.	0.5	3
237	Use of Nab-Paclitaxel Plus Gemcitabine Followed by Hypofractionated Tomotherapy With Simultaneous Integrated Boost in Patients With Locally Advanced Pancreatic Cancer. Frontiers in Oncology, 2022, 12, 782730.	1.3	4
238	Machine-Learning-Based Bibliometric Analysis of Pancreatic Cancer Research Over the Past 25 Years. Frontiers in Oncology, 2022, 12, 832385.	1.3	10
239	Radiotherapy orchestrates natural killer cell dependent antitumor immune responses through CXCL8. Science Advances, 2022, 8, eabh4050.	4.7	55
241	A phase II randomised trial of induction chemotherapy followed by concurrent chemoradiotherapy in locally advanced pancreatic cancer: the Taiwan Cooperative Oncology Group T2212 study. British Journal of Cancer, 2022, 126, 1018-1026.	2.9	11

#	ARTICLE	IF	CITATIONS
242	Current status of non-surgical treatment of locally advanced pancreatic cancer. <i>World Journal of Gastrointestinal Oncology</i> , 2021, 13, 2064-2075.	0.8	7
243	Outcomes of patients with borderline resectable and resectable pancreatic adenocarcinoma treated with neoadjuvant three-week course chemoradiotherapy using capecitabine-based versus gemcitabine-based concurrent chemotherapy. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, 2557-2566.	0.6	1
244	Treatment optimization of locally advanced and metastatic pancreatic cancer (Review). <i>International Journal of Oncology</i> , 2021, 59, .	1.4	10
245	Ablative Radiotherapy (ART) for Locally Advanced Pancreatic Cancer (LAPC): Toward a New Paradigm?. <i>Life</i> , 2022, 12, 465.	1.1	3
246	Locally advanced versus metastatic pancreatic cancer: two different diseases with two different treatment approaches?. <i>Chinese Clinical Oncology</i> , 2013, 2, 26.	0.4	0
247	New developments in the management of borderline resectable pancreatic cancer. <i>JOP: Journal of the Pancreas</i> , 2013, 14, 123-5.	1.5	2
248	Locally advanced pancreatic cancer. Looking beyond traditional chemotherapy and radiation. <i>JOP: Journal of the Pancreas</i> , 2013, 14, 337-9.	1.5	6
250	Locally advanced unresectable pancreatic cancer. <i>JOP: Journal of the Pancreas</i> , 2014, 15, 329-31.	1.5	0
251	Neoadjuvant therapy in pancreatic ductal adenocarcinoma: a competing risk analysis. <i>Surgical Practice</i> , 0, , .	0.1	0
252	Deep Penetrating Triple Responsive Prodrug Nanosensitizer Actuates Efficient Chemoradiotherapy in Pancreatic Ductal Adenocarcinoma Models. <i>Small</i> , 2022, 18, .	5.2	12
253	Phase I Trial of nab-Paclitaxel Administered Concurrently With Radiotherapy in Patients With Locally Advanced Inoperable Pancreatic Adenocarcinoma. <i>Pancreas</i> , 0, Publish Ahead of Print, .	0.5	0
254	Comparison of acute gastrointestinal toxicities between 3-dimensional conformal radiotherapy and intensity-modulated radiotherapy including prophylactic regions in chemoradiotherapy with S-1 for pancreatic cancer—importance of dose volume histogram parameters in the stomach as the predictive factors-. <i>Journal of Radiation Research</i> , 0, , .	0.8	2
255	Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a prospective, multicenter phase II trial (NEOLAP-AIO-PAK-0113). <i>ESMO Open</i> , 2022, 7, 100552.	2.0	12
256	Radiographic and Serologic Response to First-Line Chemotherapy in Unresected Localized Pancreatic Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 887-897.e3.	2.3	3
257	Nonsurgical Management of Pancreatic Adenocarcinoma. , 2022, , 535-556.		0
258	A phase II trial of gemcitabine and erlotinib followed by ChemoProton therapy plus capecitabine and oxaliplatin for locally advanced pancreatic cancer. <i>Journal of Gastrointestinal Oncology</i> , 2022, 13, 1989-1996.	0.6	1
259	A guide through conventional and modern cancer treatment modalities: A specific focus on glioblastoma cancer therapy (Review). <i>Oncology Reports</i> , 2022, 48, .	1.2	7
260	Pancreatic Adenocarcinoma Management. <i>JCO Oncology Practice</i> , 2023, 19, 19-32.	1.4	17

#	ARTICLE	IF	CITATIONS
261	High intensity focused ultrasound (HIFU) in digestive diseases: an overview of clinical applications for liver and pancreatic tumors. <i>Irbm</i> , 2022, , .	3.7	0
262	Management of Locally Advanced/Metastatic Disease: <i>Medical Oncology</i> , 2022, , 97-106.		0
263	Induction Chemotherapy With FOLFIRINOX Followed by Chemoradiation With Gemcitabine in Patients With Borderline-Resectable Pancreatic Ductal Adenocarcinoma. <i>Cancer Control</i> , 2022, 29, 107327482211344.	0.7	1
264	Stereotactic Body Radiotherapy (SBRT) of Pancreatic Cancer—A Critical Review and Practical Consideration. <i>Biomedicines</i> , 2022, 10, 2480.	1.4	6
265	Pharmacotherapeutic options for pancreatic ductal adenocarcinoma. <i>Expert Opinion on Pharmacotherapy</i> , 0, , .	0.9	4
266	Prolonged complete response after neoadjuvant capecitabine-gemcitabine for a locally advanced pancreatic adenocarcinoma: A case report. <i>Nigerian Journal of Clinical Practice</i> , 2022, 25, 1945.	0.2	0
267	Pancreatic cancers. <i>Advances in Magnetic Resonance Technology and Applications</i> , 2023, , 315-340.	0.0	0
268	Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2023, 8, 157-168.	3.7	73
269	A randomised phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer (JCOG1407). <i>European Journal of Cancer</i> , 2023, 181, 135-144.	1.3	15
270	The evolving role of radiation in pancreatic cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
271	Clinical Effects of Immuno-Oncology Therapy on Glioblastoma Patients: A Systematic Review. <i>Brain Sciences</i> , 2023, 13, 159.	1.1	1
272	A brief overview of various vaccines against nCOVID19, including safety, efficacy, reported cases, clinical trials, and progress. <i>Indian Journal of Health Sciences and Biomedical Research KLEU</i> , 2023, 16, 13.	0.1	1
273	Impact of chemoradiotherapy on the survival of unresectable locally advanced pancreatic cancer: a retrospective cohort analysis. <i>BMC Gastroenterology</i> , 2023, 23, .	0.8	0
274	Neoadjuvant therapy for pancreatic cancer. <i>Nature Reviews Clinical Oncology</i> , 2023, 20, 318-337.	12.5	61
290	Borderline Resectable and Locally Advanced Pancreatic Cancer. , 2023, , 19-35.		0